Ask AI
ProCE Banner Activity

An Expert Discussion of Novel Investigational RAS Inhibitors for Pancreatic Cancer

Clinical Thought

In this concise commentary, experts discuss the evolving field of RAS-targeted therapies for metastatic pancreatic cancer, including novel mechanisms of action, ongoing trials, and potential clinical significance.

Released: April 14, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an educational grant from Revolution Medicines, Inc.

Revolution Medicines, Inc.

Target Audience

This educational activity is intended for oncologists and other healthcare professionals who care for patients with pancreatic cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply molecular profiling to identify actionable RAS(ON) alterations in patients with advanced pancreatic ductal adenocarcinoma (PDAC)

  • Analyze clinical data from key trials evaluating emerging RAS-targeted agents for metastatic PDAC

  • Refer eligible patients with PDAC to clinical trials of investigational RAS(ON)–targeted agents

Disclosure

Primary Author

Christopher Lieu, MD, FASCO: researcher (paid to institution): Genentech, Janssen; consultant/advisor/speaker: Pfizer.

Wungki Park, MD, MS: researcher: Astellas, Lepu Bio, Merck; consultant/advisor/speaker: Astellas, Curio, EPICS, Expert Pharma, Innovent Biologics, Integrity, KeyQuest, Regeneron, Revolution Medicines; other financial or material support: Amgen, DAVA Oncology.